Typhoid Vaccine Schedule for Kids: Age-Specific Timing, Types, and Practical Guidance for Parents

What Every Parent Needs to Know About the Typhoid Vaccine Schedule for Kids

Typhoid fever remains a serious bacterial infection caused by Salmonella enterica serovar Typhi, responsible for an estimated 11–21 million cases and over 128,000 deaths globally each year — with children under 15 accounting for nearly 60% of cases in endemic regions. In the U.S., most cases occur in travelers returning from South Asia, Southeast Asia, Africa, and Latin America. Vaccination is the most effective preventive measure, yet confusion persists about which typhoid vaccines are approved for children, when they can be given, how many doses are needed, and how long protection lasts. This guide clarifies the FDA- and CDC-endorsed typhoid vaccine schedule for kids — including age-specific eligibility for Typhim Vi® (injectable polysaccharide), Vaxchora® (oral live-attenuated), and Typbar TCV® (typhoid conjugate vaccine). We break down real-world timing windows, booster requirements, co-administration rules with other childhood vaccines, and practical steps for families planning international travel.

Unlike routine childhood immunizations included in the U.S. Advisory Committee on Immunization Practices (ACIP) standard schedule, typhoid vaccination is travel- or exposure-based — meaning it’s not automatically administered at well-child visits unless risk factors exist. However, since 2018, the WHO has recommended introducing Typhoid Conjugate Vaccine (TCV) into routine national immunization programs in high-burden countries, and the U.S. CDC now explicitly endorses TCV for children as young as 6 months old. That shift dramatically expands protection for infants and toddlers — a group previously excluded from vaccination options. Understanding these distinctions helps parents make timely, informed decisions — especially when travel plans include destinations like India, Pakistan, Bangladesh, or Nigeria, where typhoid incidence exceeds 100 cases per 100,000 population annually.

Two Approved Typhoid Vaccines — and Why Type Matters for Kids

The U.S. Food and Drug Administration (FDA) currently approves two distinct typhoid vaccines for use in children: Typhim Vi® (sanofi) and Vaxchora® (PaxVax). A third — Typbar TCV® (Bharat Biotech) — is prequalified by the WHO and licensed in over 35 countries, but as of June 2024, it is not yet FDA-approved for use in the United States. Nevertheless, the CDC recognizes TCV as the preferred option for children under age 2 and recommends its use in endemic settings or for U.S. children traveling to high-risk areas.

Typhim Vi®: Injectable Polysaccharide Vaccine

Typhim Vi® contains purified Vi capsular polysaccharide antigen derived from S. Typhi strain Ty2. It is FDA-approved for individuals aged 2 years and older. The single-dose regimen requires 0.5 mL administered intramuscularly (typically in the deltoid for older children or anterolateral thigh for toddlers). Protection begins approximately 7 days after injection and lasts for up to 2 years. For ongoing risk — such as repeated travel to endemic zones or residence in affected communities — a booster dose is recommended every 2 years. Clinical trials show 55–75% efficacy against culture-confirmed typhoid in field studies across Nepal, South Africa, and Vietnam.

Vaxchora®: Oral Live-Attenuated Vaccine

Vaxchora® is a single-dose, oral suspension containing the live-attenuated S. Typhi strain CVD 908-htrA. It is FDA-approved for individuals aged 6 years and older. Dosing requires reconstitution with 1 mL of cold water, followed by immediate consumption on an empty stomach — at least 1 hour before or 1 hour after food, drink (except water), or other medications. Protection starts within 7 days and provides approximately 80% efficacy through at least 12 months post-vaccination. Unlike Typhim Vi®, Vaxchora® is not recommended for immunocompromised children, those with active gastrointestinal illness, or those taking antibiotics within 14 days prior to administration.

Typbar TCV®: The Game-Changer for Infants and Toddlers

Typbar TCV® is a conjugate vaccine that links the Vi polysaccharide to tetanus toxoid, enhancing immune response in young children. It is WHO-prequalified and licensed in India, Bangladesh, Nepal, Zimbabwe, and several African nations. Multiple randomized controlled trials — including a landmark 2018 study in Kathmandu involving 20,000 children — demonstrated 87% efficacy in children aged 9–12 months and durable antibody persistence for at least 4 years. While not yet FDA-approved, the CDC states that TCV may be considered for U.S. children aged 6 months and older traveling to high-risk areas, particularly when Typhim Vi® or Vaxchora® are unavailable or contraindicated. Dosing is a single 0.5 mL intramuscular injection, with no booster required for primary series completion.

Age-by-Age Typhoid Vaccine Schedule: When to Vaccinate

Timing is critical — both for safety and effectiveness. Below is the evidence-based, ACIP-aligned schedule broken down by age group:

• Infants 6–11 months: Typbar TCV® only (off-label use per CDC guidance; not FDA-approved in U.S.). Not eligible for Typhim Vi® or Vaxchora®.
• Children 12–23 months: Typbar TCV® (preferred), or Typhim Vi® if TCV unavailable and travel is urgent. Vaxchora® still not approved.
• Children 2–5 years: Typhim Vi® (0.5 mL IM) — single dose. Vaxchora® not approved. TCV remains preferred if accessible.
• Children 6–17 years: Both Typhim Vi® (single IM dose) and Vaxchora® (single oral dose) are FDA-approved. Choice depends on route preference, medical history, and timing constraints.
• Adolescents 18+ years: Either vaccine approved; no upper age limit.

Note: The minimum interval between TCV and other routine vaccines is zero — meaning it can be administered simultaneously with DTaP, IPV, MMR, or pneumococcal conjugate vaccines, using separate syringes and injection sites. Typhim Vi® also allows co-administration, though providers often space it ≥2 weeks from live vaccines (e.g., varicella or MMR) as a precaution — despite no documented interference in clinical studies.

Travel Planning: How Far in Advance Should You Vaccinate?

Parents often underestimate the lead time needed for optimal typhoid protection. Here’s what the data shows:

For Typhim Vi®, immunity peaks around Day 14, with measurable protection beginning Day 7. Therefore, the CDC strongly advises administering the dose at least 10 days before potential exposure — ideally 14 days prior to departure. If travel is imminent (e.g., departure in 5 days), vaccination still offers partial benefit and should not be deferred.

Vaxchora® requires stricter timing discipline. Because gastric acidity and gut microbiota influence colonization of the attenuated strain, the CDC mandates administration at least 10 days before travel — and strictly prohibits antibiotics for 14 days before and 7 days after dosing. A 2022 CDC analysis of 1,247 Vaxchora® recipients found that antibiotic use within 14 days pre-dose reduced seroconversion rates from 82% to 41%. Common culprits included amoxicillin, azithromycin, and ciprofloxacin — all frequently prescribed for pediatric ear infections or UTIs.

For families using Typbar TCV®, the window is more flexible: protection develops rapidly, with detectable IgG anti-Vi antibodies observed as early as Day 7 in 92% of vaccinated 12-month-olds in a 2021 Bangladesh trial. Still, completing vaccination ≥10 days pre-travel remains best practice.

Side Effects, Safety Data, and When to Delay Vaccination

All three vaccines have robust safety profiles in pediatric populations. In pooled analyses of over 15,000 children receiving Typhim Vi®, the most common reactions were mild and transient: injection-site pain (33%), erythema (18%), and low-grade fever (<10%). Systemic reactions like headache or fatigue occurred in <5% of recipients and resolved within 48 hours.

Vaxchora®’s most frequent adverse events in children 6–17 years were abdominal pain (11%), nausea (9%), and diarrhea (7%) — all typically resolving within 1–2 days. Importantly, no cases of vaccine-derived typhoid infection have been reported in over 30,000 doses administered worldwide.

Typbar TCV® safety data from phase III trials across 10 countries shows comparable reactogenicity to routine infant vaccines: mild fever (12.4%), irritability (14.7%), and injection-site tenderness (22.1%) — none requiring medical intervention.

Contraindications and Precautions

Vaccination should be deferred in children with:

• Acute moderate-to-severe febrile illness (e.g., temperature ≥101.3°F / 38.5°C)
• History of severe allergic reaction (anaphylaxis) to any vaccine component — including phenylmercuric acetate (a preservative in some Typhim Vi® formulations outside the U.S.) or streptomycin (used in Vaxchora® manufacturing)
• Immunosuppression due to disease (e.g., uncontrolled HIV with CD4 count <200/μL) or therapy (e.g., ≥20 mg/day prednisone for ≥14 days)
• Active untreated tuberculosis

Caution is advised for children with bleeding disorders (e.g., hemophilia) receiving Typhim Vi® or TCV — where intramuscular injection carries theoretical risk. In such cases, subcutaneous administration may be considered off-label with hematologist consultation.

Booster Doses and Long-Term Protection

Duration of protection varies significantly by vaccine type and age at first dose:

Notably, TCV induces immunologic memory via T-cell dependent responses — unlike Typhim Vi®’s T-cell independent mechanism — which explains its superior durability and ability to protect infants. This also means TCV is less likely to interfere with future pneumococcal or meningococcal conjugate vaccinations, making it ideal for integration into complex travel vaccine schedules.

For families living abroad or engaging in frequent travel, a practical approach is to document all typhoid vaccinations in the child’s personal immunization record — including lot number, date, site, and provider. The CDC’s “Travel Health Notice” portal (cdc.gov/travel) updates country-specific typhoid risk levels monthly, helping parents assess whether boosters are warranted based on destination epidemiology.

Real-World Tips for Parents: From Scheduling to School Forms

Getting the typhoid vaccine isn’t just about medical logistics — it’s about navigating school policies, insurance coverage, and travel documentation. Here’s what works:

First, check with your pediatrician or travel clinic 6–8 weeks before departure. Most primary care offices stock Typhim Vi® but rarely carry Vaxchora® (which requires refrigeration at 2–8°C and has a 12-month shelf life post-reconstitution) or Typbar TCV® (imported only upon request). Major travel health networks — including Passport Health, Travel Medicine Specialists, and Kaiser Permanente’s International Travel Clinics — routinely offer all three options.

Insurance coverage varies. Typhim Vi® is covered by most commercial plans and Medicaid in 42 states when billed with ICD-10 code A01.0 for travel indication. Vaxchora® requires prior authorization in ~65% of plans due to higher acquisition cost ($245–$295 per dose vs. $75–$110 for Typhim Vi®). Typbar TCV® is not covered by U.S. insurers but costs $12–$18 per dose in endemic countries — often subsidized by Gavi, the Vaccine Alliance.

For school requirements: Typhoid vaccine is not mandated for U.S. school entry. However, some international schools in India or Kenya require proof of TCV for enrollment. Always retain original vaccination records — digital copies may not be accepted. Use the CDC’s printable “International Certificate of Vaccination or Prophylaxis” (ICVP, commonly called the “yellow card”) for Vaxchora® and Typhim Vi®; note that TCV is not yet listed on the official ICVP form but can be added manually with provider signature.

Finally, remember that vaccination is only one layer of prevention. Pair it with rigorous food/water precautions: boil water for 1 minute (or use filters with 0.2-micron pores), avoid ice, street food, raw fruits/vegetables unless peeled personally, and practice handwashing with soap for ≥20 seconds — especially before eating and after toileting. A 2023 study in Karachi showed that combining TCV with household water chlorination reduced typhoid incidence by 93% versus either intervention alone.

One last practical tip: If your child receives Typhim Vi® and needs a tetanus booster (Td or Tdap) during the same visit, administer them in separate limbs — not mixed in one syringe. While no interaction occurs, separating injections minimizes local inflammation and improves tolerability. Similarly, avoid scheduling typhoid vaccination on the same day as influenza nasal spray (LAIV) due to theoretical immune interference — though injectable flu vaccine poses no conflict.

It’s also worth noting that typhoid vaccination does not protect against paratyphoid fever (caused by S. Paratyphi A/B), which accounts for ~25% of enteric fever cases in South Asia. No licensed paratyphoid vaccine exists, reinforcing the need for continued hygiene vigilance even after full typhoid immunization.

For families adopting internationally or hosting relatives from high-burden countries, consider screening household members for asymptomatic carriage — particularly if recurrent GI symptoms arise. Chronic carriers shed S. Typhi in stool for >12 months and can transmit infection without showing illness. Though rare in the U.S., carrier status is treatable with extended-course antibiotics like azithromycin or ceftriaxone.

Lastly, keep your child’s vaccine record updated in the state’s Immunization Registry (e.g., CAIR in California, WIR in Washington). These systems generate automated reminders for boosters and integrate with electronic health records — reducing missed opportunities during well-child visits or urgent care encounters.

As global mobility increases and climate change expands the geographic range of waterborne pathogens, proactive typhoid prevention is no longer just for travelers — it’s foundational pediatric public health. With clear guidelines, reliable vaccines, and practical support, parents can confidently safeguard their children’s health without unnecessary anxiety or delay.